Hakim Bouterfa

Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors

Roelf Valkema, Stanislas Pauwels, Larry K. Kvols et al. · Seminars in Nuclear Medicine · 2006 · 313 citations

Medicine, Nuclear Medicine, Oncology +14

⁹⁰Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide

David Bushnell, Thomas M. O’Dorisio, M. Sue O’Dorisio et al. · Journal of Clinical Oncology · 2010 · 304 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion

François Jamar, Raffaella Barone, Isabelle Mathieu et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2003 · 240 citations

Pharmacy, Pharmacokinetics, Pharmacology +8

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR^® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegaly

Moisés Mercado, Fátima Borges, Hakim Bouterfa et al. · Clinical Endocrinology · 2007 · 210 citations · Full text

Pharmacy, Endocrinology, Pharmacotherapy +9

Sensitivity Comparison of ⁶⁸Ga-OPS202 and ⁶⁸Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study

Guillaume Nicolas, N. Schreiter, Felix Kaul et al. · Journal of Nuclear Medicine · 2017 · 164 citations · Full text

Medicine, Nuclear Medicine, Oncology +17